We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Bone Cell Growth Therapy for Osteoporosis

By HospiMedica staff writers
Posted on 11 May 2001
The first clinical trial is under way of an experimental way to grow new bone to replace bone that has been lost because of osteoporosis. More...
Currently, almost all treatments for osteoporosis aim only at preventing further bone loss.

The new therapy uses a patient's own bone marrow to grow new cells and strengthen existing bones. The procedure involves taking a small amount of bone marrow out of the patient, placing it in a special device that grows these cells to very, very large numbers and then injecting them back into the patient. The cells produced will be a mixture of both blood-forming and bone-forming cells, which will hone in on places in the body that have bone. The procedure employs a system of producing human cells outside the body called Replicell, which was developed by Aastrom Biosciences, Inc. (Ann Arbor, MI, USA). The procedure is under investigation by researchers at the University of Michigan Health System (UMHS, Ann Arbor, USA).

The therapy is being tested on people with significant osteoporosis and is not designed for patients who have minimal bone loss or for those who are concerned about bone loss. "We don't know yet because this is an experimental process, but we think that any bone that we can give patients--given the fact that they're growing their own bone—will be good bone, strong bone, healthy bone, and will make it possible for them to have a more active lifestyle with less risk of fracture,” said Robert Lash, co-director of the UMHS Osteoporosis and Metabolic Bone Disease Program.




Related Links:
Aastrom Biosciences Inc

Gold Member
12-Channel ECG
CM1200B
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Hemostatic Agent
HEMOBLAST Bellows
Emergency Ventilator
Shangrila935
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: The collaboration will integrate Masimo’s innovations into Philips’ multi-parameter monitoring platforms (Photo courtesy of Royal Philips)

Philips and Masimo Partner to Advance Patient Monitoring Measurement Technologies

Royal Philips (Amsterdam, Netherlands) and Masimo (Irvine, California, USA) have renewed their multi-year strategic collaboration, combining Philips’ expertise in patient monitoring with Masimo’s noninvasive... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.